twirla

Generic: ethinyl estradiol and levonorgestrel

twirla: developed by 2 companies · 1 FDA decision. Updated within the last hour.

Development Pipeline (2)

CompanyPhase
AGILE THERAPEUTICS INC (AGRX)Approved
Corium International, Inc. (CORI)Phase 3

FDA Decisions

Approval1 INDICATIONS AND USAGE TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. Limitation of Use Consider TWIRLA’s reduced effectiveness in women with a BMI ≥ 25 to < 30 kg/m 2 before prescribing TWIRLA [see Use in Specific Populations ( 8.9 ) and Clinical Studies ( 14 )] . TWIRLA is contraindicated in women with a BMI ≥ 30 kg/m 2 [see Contraindications ( 4 )] . TWIRLA is a comb(AGRX)

Frequently asked questions

Who is developing twirla?

twirla is being developed by AGILE THERAPEUTICS INC, Corium International, Inc..

What is twirla's latest FDA decision?

The most recent tracked FDA decision for twirla is Approval for 1 INDICATIONS AND USAGE TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. Limitation of Use Consider TWIRLA’s reduced effectiveness in women with a BMI ≥ 25 to < 30 kg/m 2 before prescribing TWIRLA [see Use in Specific Populations ( 8.9 ) and Clinical Studies ( 14 )] . TWIRLA is contraindicated in women with a BMI ≥ 30 kg/m 2 [see Contraindications ( 4 )] . TWIRLA is a comb, dated February 14, 2020.

Get deeper analysis on twirla

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    twirla — Drug Pipeline, Trials & FDA Status | BioSniper